A new drug application from the U.S. Food and Drug Administration (FDA) has been accepted for Viekira Pak -- including ombitasvir, paritaprevir and ritonavir tablets, as well as dasabuvir tablets -- which is an oral treatment indicated for use by patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection.
Viekira Pak is a product of global pharmaceutical company AbbVie, which is based in Chicago, Illinois. It is an oral medication.
According to U.S. Centers for Disease Control (CDC) statistics, 2.7 million Americans are living with HCV infections, the most common of which is genotype 1 (approximately 74 percent).
"Nearly one year after the launch of Viekira Pak, AbbVie is pleased to announce the acceptance of a New Drug Application for a once-daily formulation for the treatment of patients with chronic genotype 1 hepatitis C," Dr. Michael Severino, AbbVie's chief scientific officer, said. "This milestone further underscores AbbVie's commitment to offer people living with hepatitis C optimized treatment options."
More information about Viekira Pak and AbbVie's other products is available online at www.abbvie.com or on the company's Facebook and Twitter pages.
AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Labs.
